Wedbush Positive on Alexion (ALXN) Amid Achillion Acquisition

October 16, 2019 10:17 AM EDT Send to a Friend
Wedbush analyst Laura Chico reiterated an Outperform rating and $146.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) after the company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login